0001209191-20-007477.txt : 20200207 0001209191-20-007477.hdr.sgml : 20200207 20200207160854 ACCESSION NUMBER: 0001209191-20-007477 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200205 FILED AS OF DATE: 20200207 DATE AS OF CHANGE: 20200207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arbuckle Stuart A CENTRAL INDEX KEY: 0001557290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20587467 MAIL ADDRESS: STREET 1: VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-05 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001557290 Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2020-02-05 4 A 0 12136 0.00 A 45376 D Common Stock 2020-02-05 4 A 0 9800 0.00 A 55176 D Common Stock 2020-02-05 4 A 0 12387 0.00 A 67563 D Common Stock 2020-02-06 4 M 0 1564 187.53 A 69127 D Common Stock 2020-02-06 4 M 0 1223 155.57 A 70350 D Common Stock 2020-02-06 4 S 0 1511 238.71 D 68839 D Common Stock 2020-02-06 4 S 0 725 239.47 D 68114 D Common Stock 2020-02-06 4 S 0 230 240.53 D 67884 D Common Stock 2020-02-06 4 S 0 150 241.08 D 67734 D Common Stock 2020-02-06 4 S 0 171 242.47 D 67563 D Common Stock 140 I 401(k) Stock Option (Right to Buy) 187.53 2020-02-06 4 M 0 1564 0.00 D 2029-02-05 Common Stock 1564 18770 D Stock Option (Right to Buy) 155.57 2020-02-06 4 M 0 1223 0.00 D 2028-02-05 Common Stock 1223 9783 D Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020. Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. The earned performance shares will vest in installments beginning on 02/24/2020. Restricted stock unit award that vests in installments beginning on 02/10/2021. Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $238.71 (range $238.07 to $239.05). Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $239.47 (range $239.11 to $240.04). Open market sales reported on this line occurred at a weighted average price of $240.53 (range $240.40 to $240.60). Open market sales reported on this line occurred at a weighted average price of $241.08 (range $241.04 to $241.12). The option vests in 16 quarterly installments from 02/06/2019. The option vests in 16 quarterly installments from 02/06/2018. /s/ Omar White, Attorney-in-Fact 2020-02-07